These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 16925486)

  • 1. Breast cancer susceptibility testing: past, present and future.
    Goldberg JI; Borgen PI
    Expert Rev Anticancer Ther; 2006 Aug; 6(8):1205-14. PubMed ID: 16925486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
    Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
    Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRCA-1 and BRCA-2 mutations as prognostic factors in clinical practice and genetic counselling.
    Nicoletto MO; Donach M; De Nicolo A; Artioli G; Banna G; Monfardini S
    Cancer Treat Rev; 2001 Oct; 27(5):295-304. PubMed ID: 11871866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preventing future cancers by testing women with ovarian cancer for BRCA mutations.
    Kwon JS; Daniels MS; Sun CC; Lu KH
    J Clin Oncol; 2010 Feb; 28(4):675-82. PubMed ID: 19841329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations.
    Fatouros M; Baltoyiannis G; Roukos DH
    Ann Surg Oncol; 2008 Jan; 15(1):21-33. PubMed ID: 17940826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2.
    Kauff ND; Barakat RR
    J Clin Oncol; 2007 Jul; 25(20):2921-7. PubMed ID: 17617523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations of BRCA genes in hereditary breast and ovarian cancer.
    Radice P
    J Exp Clin Cancer Res; 2002 Sep; 21(3 Suppl):9-12. PubMed ID: 12585647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hereditary breast-ovarian cancer: clinical findings and medical management.
    Marshall M; Solomon S
    Plast Surg Nurs; 2007; 27(3):124-7. PubMed ID: 17901820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRCA1 and BRCA2: the genetic testing and the current management options for mutation carriers.
    Palma M; Ristori E; Ricevuto E; Giannini G; Gulino A
    Crit Rev Oncol Hematol; 2006 Jan; 57(1):1-23. PubMed ID: 16337408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening and prevention of hereditary gynecologic cancers.
    Kehoe SM; Kauff ND
    Semin Oncol; 2007 Oct; 34(5):406-10. PubMed ID: 17920895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BCoR-L1 variation and breast cancer.
    Lose F; Arnold J; Young DB; Brown CJ; Mann GJ; Pupo GM; ; Khanna KK; Chenevix-Trench G; Spurdle AB
    Breast Cancer Res; 2007; 9(4):R54. PubMed ID: 17697391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hereditary breast and ovarian cancer (HBOC): clinical features and counseling for BRCA1 and BRCA2, Lynch syndrome, Cowden syndrome, and Li-Fraumeni syndrome.
    Shulman LP
    Obstet Gynecol Clin North Am; 2010 Mar; 37(1):109-33, Table of Contents. PubMed ID: 20494261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel germline BRCA1 and BRCA2 mutations in Turkish women with breast and/or ovarian cancer and their relatives.
    Egeli U; Cecener G; Tunca B; Tasdelen I
    Cancer Invest; 2006; 24(5):484-91. PubMed ID: 16939956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of BRCA1 and BRCA2 mutation carrier prediction models in breast and/or ovarian cancer families of French Canadian descent.
    Oros KK; Ghadirian P; Maugard CM; Perret C; Paredes Y; Mes-Masson AM; Foulkes WD; Provencher D; Tonin PN
    Clin Genet; 2006 Oct; 70(4):320-9. PubMed ID: 16965326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hereditary breast cancer: part II. Management of hereditary breast cancer: implications of molecular genetics and pathology.
    Silva E; Gatalica Z; Snyder C; Vranic S; Lynch JF; Lynch HT
    Breast J; 2008; 14(1):14-24. PubMed ID: 18086271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modifiers of risk of hereditary breast and ovarian cancer.
    Narod SA
    Nat Rev Cancer; 2002 Feb; 2(2):113-23. PubMed ID: 12635174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Preventive surgical prcedures for inherited risk of breast cancer].
    Menke-Pluymers MB; Seynaeve C; van Geel AN; Klijn JG; Meijers-Heijboer EJ; Eggermont AM
    Ned Tijdschr Geneeskd; 2005 Nov; 149(48):2663-7. PubMed ID: 16358615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Genetic testing in patients at risk for carcinoma of the breast].
    Kiechle M
    Dtsch Med Wochenschr; 2006 Oct; 131(43):2420-2. PubMed ID: 17054060
    [No Abstract]   [Full Text] [Related]  

  • 19. [Recommendations for the management of women with an increased genetic risk of gynaecological cancer].
    Verheijen RH; Boonstra H; Menko FH; de Graaff J; Vasen HF; Kenter GG
    Ned Tijdschr Geneeskd; 2002 Dec; 146(50):2414-8. PubMed ID: 12518519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening for a BRCA2 rearrangement in high-risk breast/ovarian cancer families: evidence for a founder effect and analysis of the associated phenotypes.
    Machado PM; Brandão RD; Cavaco BM; Eugénio J; Bento S; Nave M; Rodrigues P; Fernandes A; Vaz F
    J Clin Oncol; 2007 May; 25(15):2027-34. PubMed ID: 17513806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.